hTNFR2(BALB/c)

Nomenclature

BALB/cAnSmoc-Tnfrsf1btm(hTNFRSF1B)Smoc

Cat. NO.

NM-HU-220499

Strain State

Embryo cryopreservation

Export PDF

Gene Summary

Gene Symbol
TNFRSF1B

Model Description

The endogenous mouse Tnfrsf1b gene was replaced by human TNFRSF1B gene.

Validation Data

image.png

Fig.1 Expression analysis of hTNFR2 on Treg cells in spleen of hTNFR2(BALB/c) humanized mice. 

Leukocytes were collected from spleen of wild-type BALB/c mice (female, 8 weeks) and homozygous hTNFR2(BALB/c) mice (male, 14 weeks) stimulated in vivo with anti-CD3ε and analyzed by flow cytometry with anti-mTNFR2 and anti-hTNFR2. hTNFR2 were exclusively detectable in hTNFR2 humanized mice but not in wild-type mice.

image.png

Fig.2 Expression analysis of hTNFR2 on DCs, monocyte, B cells, and neutrophils in spleen of hTNFR2(BALB/c) humanized mice. 

Leukocytes were collected from spleen of wild-type balb/c mice (female, 12 weeks) and homozygous hTNFR2(BALB/c) mice (male, 18 weeks), and analyzed by flow cytometry with anti-mTNFR2 and anti-hTNFR2. hTNFR2 were exclusively detectable in hTNFR2 humanized mice but not in wild-type mice.

image.png

Fig.3 Expression analysis of hTNFR2 on monocyte, B cells, and neutrophils in blood of hTNFR2(BALB/c) humanized mice. 

Leukocytes were collected from blood of wild-type balb/c mice (female, 12 weeks) and homozygous hTNFR2(BALB/c) mice (male, 18 weeks), and analyzed by flow cytometry with anti-mTNFR2 and anti-hTNFR2. hTNFR2 were exclusively detectable in hTNFR2 humanized mice but not in wild-type mice.


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more